Skip to content

Innate Lymphoid Cells of the Lung

Citation

  • Verified title: Innate Lymphoid Cells of the Lung
  • Publication year: 2019
  • DOI: 10.1146/annurev-physiol-020518-114630
  • Metadata source: crossref-title (confidence: high)
  • Original local title: Innate Lymphoid Cells of the Lung

Ingest Mode

  • Mode: focused manual crystallization mode
  • Meaning: this source page was manually reviewed for source text, model context, assay directness, and claim boundaries.
  • Durable synthesis status: selected source-specific claims were propagated into entity/topic/digest pages only where evidence strength and context labels are preserved.

Source Type

  • lung ILC review
  • Evidence profile: review-level synthesis of lung-resident innate cells, ILC1/ILC2/ILC3/NK functions, asthma, infection, repair, and tumor surveillance context.
  • Knowledge note status: source-reviewed review note suitable for orientation and source routing, not primary mechanistic confidence.

Evidence Profile

  • Overall confidence: medium for review-level lung ILC framing; individual mechanistic claims require primary source support.
  • Evidence tags: #source/review #species/mixed #tissue/lung #cell/ILC1 #cell/ILC2 #cell/ILC3 #cell/NK #outcome/infection #outcome/inflammation #outcome/repair #outcome/tumor #axis/ILC_lung_homeostasis #axis/ILC_airway_inflammation #status/focused_crystallization
  • Primary biological axis: lung ILC subsets as tissue-positioned contributors to defense, allergy, repair, and immune pathology.

Why It Matters Here

This review gives readers a lung-specific orientation layer for the wiki. It should route users into primary sources rather than serving as the main evidence for any mechanistic claim.

Key Findings

  • The review frames the lung as a non-lymphoid organ with a coordinated innate immune network that includes epithelial cells, dendritic cells, macrophages, NK cells, and ILCs.
  • It summarizes ILC1, ILC2, and ILC3 effector logic around IFN-gamma, IL-5/IL-13, and IL-17A/IL-22 outputs.
  • It places lung ILCs across infection, allergy, repair, and tumor-related contexts.
  • Its best wiki role is orientation and terminology, not primary proof.

Claim-Level Confidence

  • Medium confidence: lung ILCs are a useful organizing frame for pulmonary barrier immunity.
  • Low-to-medium confidence: source-specific mechanistic details should be traced to primary papers before being used as durable claims.
  • Low confidence: this review alone should not support therapeutic, causal, or disease-endotype claims.

Methods and Context

  • Source type: narrative review.
  • Evidence directness: synthesis and citation routing.
  • Best wiki use: introductory lung ILC overview, reading route, and terminology alignment.

Caveats

  • Keep review-level evidence distinct from primary evidence.
  • Do not let overview language erase species, disease, or tissue-compartment boundaries.
  • Use primary source pages for claim-level confidence.

Contradiction and Supersession

  • Contradiction status: helps explain why lung ILCs can appear protective, pathogenic, or reparative depending on context.
  • Supersession status: not superseded; orientation value remains, with newer primary sources carrying stronger claim confidence.

Pages Updated From This Source